Grants Search Results

Based on progress to date, Dr. Wang, was awarded a new grant in 2016 to fund an additional year of this Scholar award. AML (acute myelogenous leukemia) is an often-fatal disease in children and adolescents. Part of the reason for limited success in curing AML is that current therapies don't attack the cancer stem cells that are responsible for maintaining the leukemia. Dr. Wang's research seeks to identify specific ways to target those hard-to-kill AML stem cells. To do this Dr. Wang is using the cutting-edge technologies of phosphoproteomics, which allow researchers to look at biologically vital pathways in cancer stem cells in a comprehensive, efficient, and novel manner. Awarded at Children's Hospital Boston and transferred to City of Hope.

A portion of this research was funded by P.A.L.S. Bermuda with funds raised through the St. Baldrick's Foundation.

Based on progress to date, Dr. Pinto, was awarded a new grant in 2016 to fund an additional year of this Scholar award. Prior to his 2015 relocation to Seattle, Dr. Pinto was the FOX Schools Challenge St. Baldrick's Scholar. He studies neuroblastoma, a childhood cancer of the nervous system. Factors such as patient age, extent of tumor spread, and tumor genetics are used to identify patients at highest risk of relapse, and these patients receive the most aggressive treatment. Despite this, more than half of these high-risk patients will die of disease. This project is using patient genetics to identify children that may be resistant to chemotherapy, allowing researchers to further refine the risk stratification and alter therapy for those patients at highest risk of relapse, to ultimately cure more children of this devastating disease. Awarded at the University of Chicago and transferred to Seattle Children's Hospital.

A portion of this grant was named for the FOX Schools Challenge, created in 2007 when Chicago area schools and students began to rally around the mission to Conquer Childhood Cancers, inspiring more than 15,000 people to shave and raising more than $5 million for childhood cancer research through the St. Baldrick's Foundation.

Filemon Dela Cruz, M.D., NetApp St. Baldrick's Scholar, studies ewing sarcoma, a common cancer of the bone and tissues in children. Despite our best therapies, less than 20% of children with widespread disease will survive. Dr. Dela Cruz's lab recently developed a model of Ewing sarcoma that has been genetically altered to mimic the early stages of this disease. This project aims to use this model to identify the biologic steps that went wrong in a cell to create Ewing's sarcoma, so that researchers can devise ways to correct and prevent these mistakes from ever occurring.

This grant is named for the NetApp team, whose employees around the world have raised more than $3 million for lifesaving research through the St. Baldrick's Foundation.

Based on progress to date, Dr. Vanan, was awarded a new grant in 2016 to fund an additional year of this Scholar award. Issai Vanan, M.D., M.P.H., studies medulloblastoma, the most common malignant brain tumor in children. High-risk medulloblastoma patients have low disease-free survival. Radiotherapy used in its treatment has significant long-term side-effects and new therapeutic strategies are needed that will minimize these side effects. The goals of this project are to validate and study the clinical importance of genes that may play a role in radiation resistance of medulloblastomas. Dr. Vanan hopes to identify new therapeutic targets/drugs that are therapeutic while using much lower doses of radiation, thereby reducing the negative side effects of radiotherapy. A portion of the grant was named in loving memory of Fr. Peter J. McKenna, beloved brother of former St. Baldrick's board member John McKenna, and in honor of John's incredible dedication and service. Awarded at The Feinstein Institute for Medical Research and transferred to CancerCare Manitoba.

About 80% of children and adolescents diagnosed with cancer become long-term survivors. About half of them develop therapy-induced hearing loss that is cumulative and irreversible. Most at risk are patients with brain tumors, neuroblastomas, osteosarcomas, soft tissue sarcomas, retinoblastomas, hepatoblastomas, or germ cell tumors who need to be treated with cisplatin, combinations of cisplatin and carboplatin, radiation to the head and neck, or combinations of platins and radiation. Therapy-induced hearing loss adversely affects speech and language development, reading ability, communication, academic performance and psychosocial development. It frequently causes stress, social isolation, low self-esteem, and low overall quality of life. This project explores the use of moderate to high doses of dietary selenium as means to reduce or prevent cisplatin-induced hearing loss.

Adaptive cell therapy involves engineering the body's own immune cells, called T-cells, to fight cancer. The T-cells are engineered to target a protein which is present only in the cancer cells, but not in normal cells. One such protein, WT-1 is expressed only in leukemia cells and has proven to be an effective target, for a specific type of T cells called CD8 T-cells. However, these CD8 T-cells do not persist and leukemias recur. Dr. Anur Praveen, PartnerRe St. Baldrick's Fellow, is studying whether another type of T-cells called CD4 T-cells alone can eradicate leukemia or these CD4 T cells can help the CD8 T-cells to last longer and fight leukemia without recurrence. This grant is named for PartnerRe, a global reinsurance company who has raised over $1 million to fund childhood cancer research through the St. Baldrick’s Foundation.

This grant helps provide staffing to ensure that more kids can be treated on clinical trials, their best hope for a cure, at this institution.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Multidisciplinary Childhood ALL SPORE Planning Grant. For a description of this project, see the consortium grant made to the lead institution: the New York University Shool of Medicine, New York, NY.

This grant helps provide necessary resources at this institution to ensure that more kids can be treated on clinical trials, their best hope for a cure.

This grant helped provide necessary resources at this institution to allow investigators to study the biology of cancers and also to test new drugs in preparation for developing clinical trials, especially for acute lymphoblastic leukemia (ALL) and Wilms tumor.

This grant helps provide necessary resources and staff support at this institution to ensure that more kids can be treated on clinical trials, their best hope for a cure.

This grant funds a Clinical Research Assistant to ensure that more kids can be treated on clinical trials, their best hope for a cure, at this institution.

With acute lymphoblastic leukemia (ALL) patients facing a 20% chance of relapse and poor prognosis, as well as substantial short and long term side effects from conventional therapy, novel approaches using targeted therapy based on the intrinsic biology of the ALL blast are urgently needed. The SPORE in Childhood ALL is an ambitious multi-institutional grant that brings together a talented and productive group of basic, translational and clinical investigators who have a strong history of collaborative efforts.  There has never been a SPORE focused on childhood cancer in the history of the National Cancer Institute (NCI), and this grant funds the planning necessary to submit the SPORE for NCI approval.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Multidisciplinary Childhood ALL SPORE Planning Grant. For a description of this project, see the consortium grant made to the lead institution: the New York University Shool of Medicine, New York, NY.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Multidisciplinary Childhood ALL SPORE Planning Grant. For a description of this project, see the consortium grant made to the lead institution: the New York University Shool of Medicine, New York, NY.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Multidisciplinary Childhood ALL SPORE Planning Grant. For a description of this project, see the consortium grant made to the lead institution: the New York University Shool of Medicine, New York, NY.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Multidisciplinary Childhood ALL SPORE Planning Grant. For a description of this project, see the consortium grant made to the lead institution: the New York University Shool of Medicine, New York, NY.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Multidisciplinary Childhood ALL SPORE Planning Grant. For a description of this project, see the consortium grant made to the lead institution: the New York University Shool of Medicine, New York, NY.

Based on progress to date, Dr. Cho, Miracles for Michael St. Baldrick's Scholar, was awarded a new grant in 2014 to fund an additional two years of this Scholar award. Medulloblastoma is the most common brain cancer in children. Currently, these children undergo surgery and aggressive radiation and chemotherapy, and still about 35% do not survive. Survivors are often left with permanent disabilities with learning, strength and coordination. There is a critical need for newer, more 'targeted' therapies that will not only increase survival of patients, but also prevent damage to the normal brain. The goal of Dr. Cho's research is to identify the molecular factors that medulloblastomas rely on for growth and survival, in order to develop new strategies to more effectively treat children diagnosed with this lethal disease. Awarded at Children's Hospital Boston, transferred to Stanford University, and transferred to Oregon Health & Science University.

This grant is named for the “Miracles for Michael” Hero Fund created in memory of Michael Orbany and honors his tremendous strength to never ever give up.

To treat cancer effectively we must first understand why cancer develops. The body is constantly producing cells which make up our tissues. Often, when a cell develops chromosomal damage, the cell is fixed by multiple proteins referred to as the DNA Damage Response (DDR), or the cell is eliminated through a process called apoptosis. Unfortunately, some damaged cells escape these processes because the DDR does not work properly, and they go on to divide and form cancer. This project focuses on understanding one aspect of the DDR, a protein called SMARCAL1, to gain insight into why normal cells become genetically unstable and cancerous, and to uncover proteins and pathways that might serve as novel targets for cancer drugs, to help eventually eradicate of childhood cancer.